News & Events

View all our next events

Cell line development involves multiple complex processes requiring consistency and reproducible results.

During the development of a chromatographic method, different parameters must be investigated. In order to reduce the method development timing, a QbD based approach, which allows also to verify the impact of combination among different parameters, is encouraged by recently published ICHQ14 guidance.

Looking across the workflow the webinar discussed the benefits of the cell line development Freedom™ ExpiCHO-S™ Kit, their evaluation of the revolutionary Thermo Scientific™ DynaDrive™ Single Use Bioreactor (S.U.B.)

CD205/Ly75, was selected as target antigen for a humanized anti-CD205 IgG1 conjugated to the DM4 toxin, MEN1309. The over expression of CD205 in different solid cancers, combined with its capability to induce ligand internalization, were key factors in the election of CD205 to excellent target for an Antibody Drug Conjugate (ADC).

Chimeric Antigen Receptors (CARs) are artificial receptors composed of a region targeting a specific antigen linked, through an intracytoplasmic domain, to the T cell activation domain CD3zeta chain (first-generation CAR).

Development of a robust and reproducible biopharmaceutical process for production of monoclonal Antibodies (mAbs) is a critical path activity in the overall process development timeline.

The OPBG - together with the project partners the Istituto Nazionale Tumori Regina Elena (IFO), Menarini Biotech, Takis and Plaisant - organizes the final event to be held on 12 December 2022 at the "Valerio Nobili" Auditorium ( San Paolo)

The aim of the work was to develop a cell cultivation process capable of increasing the productivity of a CHO-S cell line engineered to express a bispecific antibody.

Creating highly productive clonal cell lines for Monoclonal Antibody (mAb) production is time-consuming, labor-intensive, and costly, since achieving consistent cell culture performance requires careful screening, selection, and optimization of media formulations and feed.

New publication from Menarini Biotech on Sept 2019 Issue of Bioprocess International Cell Line Development Featured Report: "Streamlined Serum-Free Adaptation of CHO-DG44 Cells". Authors: "Moroni, Annarita Di Nunzio, Rosa Puca, Lavinia Nardinocchi, Kimesha Hammet, Graziella Piras, James Brooks, and Leonardo Sibilio."

"Menarini Biotech was awarded among the winners of Lazio Innova's KETs-Key Enabling Technologies with the "MenHub" project. In this way Menarini Biotech becomes part of the Community of Innovators of the Lazio Region, which aims to enhance the wealth of knowledge and technologies in the field of pharmaceutical biotechnology and promote technological transfer".

Menarini Biotech has been included in the BOOK “Attrazione per gli investimenti”, distributed at the Bio International Convention of Philadelphia 2019, within the Italy Country Presentation. We presented our partnership with Takis and IBI-Lorenzini offering a streamlined one-stop-shop solution for early stage biotech companies who wish to get their mAbs or recombinant proteins in clinical trial quickly and reliably.

Menarini-Biotech will participate at the ESACT Meeting taking place May 5th - 8th 2019 at Copenhagen, Denmark. We'll be available to discuss potential Strategic Partnerships and Collaborations in Biopharmaceutical Drug Development & GMP Manufacturing.

We will be at Pharma Contract Manufacturing 2019, being available to discuss potential Strategic Partnerships and Collaborations in Biopharmaceutical Drug Development & Manufacturing

Project MenHub concerning “Creation of an industrial attraction pole for biotech companies in Lazio based on molecular technology DEPArrayTM ”, co-funded by Lazio Innova (Key Enabling Technologies – 2018), has started on January 2, 2018 and it will finish on June 30, 2019.

We were at Biopronet 5th Annual Science meeting 2018 with a poster concerning “A DOE Approach to Oxygen Transfer Modelling for Single Use Bioreactors at Multiple Scales “, in collaboration with ROK Bioconsulting.

We were at Bioproduction 2018 with an oral presentation concerning “Accelerated Media and Feed Development through Use of Media and Feed Library Screening”. We presented data obtained in collaboration with Beckton and Dickinson.

Menarini Biotech has established a UK Branch of its process development laboratories at the newly constructed Thames Valley Science Park in Reading, UK. Occupying 400m2 of lab and office space the UK Branch

We will be at Bioprocessing Summit Europe 2019 with an oral presentation concerning “A DOE Approach to Oxygen Transfer Modelling in Single-Use Bioreactors”, in collaboration with ROK Bioconsulting.

Meet us at the ASCO

We’ll be at the Meet2Win Oncology Business Convention, Bordeaux, May 11-12, 2017

Meet Menarini Biotech at the IATI BioMed in Tel Aviv, May 18-20, 2015..

We will be at the BIO International looking for new opportunities

We’ll be at the Meet in Italy for life Sciences 2015, September 2017

We’ll be at the AACR, April 1-5, washington.

We will attend the BioPharma America, Boston, Sept 26-27, 2017.

We will attentd the Bio Europe 2017 in Berlin, Nov 6-8, 2017

Exploring the latest market access and regulatory and technical developments, we’ll be exhibiting at Biosimilars and Biotech Turkey & MENA, Istanbul, 18-19 November. Arrange a meeting, or drop by the stand.

We’ll be at Biotech Showcase on the 12-14 January, 2015 in San Francisco.